Dr. Danso moderated this afternoon’s #ASCO23 metastatic breast cancer session where Erika Hamilton, MD delivered exciting data on a phase 2 HER3-Dxd study Daiichi Sankyo #VirginiaOncologyAssociates

Drug companies Moderna and Merck have released encouraging results from a vaccine trial that shows promise in the battle against Stage 3 and Stage 4 melanoma, the most serious type of skin cancer. Dr. Natalie Azar breaks down the findings.

Ocular Melanoma A Cure In Sight July 22 Seminar join us for up to date discussion on therapeutics. HonorHealth Research Institute The Angeles Clinic Sarah Cannon Docs Meredith McKean MD, MPH Lauren A. Dalvin, MD Mayo Clinic Department of Ophthalmology Immunocore Foghorn Therapeutics Castle Biosciences acureinsight.org/education-even…

7th AIM at Melanoma Foundation Women in Melanoma #WIM meeting. Absolutely my favorite meeting of the year- these women are such role models to me and have shaped my career in countless ways. Sunandana Chandra, MD Janice Mehnert, MD Pauline Funchain Bella Glitza, MD, PhD Sapna Patel Katy Tsai, MD

We are thrilled to announce SCRI Oncology Partners! With this expansion of the SCRI network, we build upon our capabilities and will undertake new groundbreaking studies that will continue our mission to advance cancer care. usoncology.com/news/the-us-on…

Adjuvant #melanoma phase 2 of pembro +/- individualized neoantigen therapy (mRNA-4157/V940; KEYNOTE-942) The Lancet! Excited to be part of this trial & helping to lead on-going Ph3 (NCT05933577). Just might be the next big thing for cancer in general... sciencedirect.com/science/articl…

DKN-01 Plus Bevacizumab and Chemotherapy Shows Tolerability, Activity in MSS CRC @meredithpelster Sarah Cannon Docs @asco #GI24 #crcsm onclive.com/view/dkn-01-pl…

SCRI’s Dr. Meredith McKean MD, MPH takes the #ASCO24 stage in the “PD-1-Refractory Advanced Melanoma: How Do We Get to the Finish Line?” session as a discussant covering key #melanoma takeaways.

Presented at #ASCO24: Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: nej.md/3wSo3uk

Amazing results of neoadjuvant low-dose ipi+nivo leading to statistically significant improvement in EFS HR (0.32 , p<0.0001)over surgery + adjuvant therapy, NADINA presented beautifully by Christian Blank congrats to entire field #INMC great news for pts w resectable melanoma

So proud of David R. Spigel, MD, FASCO for an excellent presentation of transforming results with consolidation durvalumab in small cell #lcsm 🫁 Big win for patients! Sarah Cannon Docs

SCRI’s David R. Spigel, MD, FASCO presented important updates from the ADRIATIC study for limited stage small cell lung cancer. An exciting day in #lungcancer with results from LAURA study as well as ADRIATIC study, proving again that Today’s Clinical Trials are Tomorrow’s Therapies #ASCO24

Our own Prof. Roda Amaria ⁦MD Anderson Cancer Center⁩ presenting first results of engineered T cell therapy OBX-115, eliminates need for IL-2, inducible & regulatable construct with oral acetazolamide. Impressive safety & early efficacy data ORR 44% , 22% CR ICI refractory disease

#ASCO24, Suthee Rapisuwon, MD Georgetown Lombardi reported on a phase II study of adjuvant nivolumab in combination with ipilimumab in high-risk UM patients. Encouraging results show improvement in distant metastasis-free survival (DMFS) in those that received #adjuvant therapy.

Integrating 15-GEP with PRAME expression status into a 4-group prognostic classification system showed prognostic accuracy in uveal melanoma. #melsm #oncology onclive.com/view/integrate…

⭐️☀️🌞Fantastic day & amazing weather in Nashville, TN for a morning walk with the melanoma clinical research #Dreamteam Sarah Cannon Docs SCRI Oncology Partners supporting the AIM at Melanoma Foundation for melanoma awareness, education & research Meredith McKean MD, MPH Ishwaria Subbiah, MD MS FASCO Erika Hamilton, MD

☀️Amazing day for a morning walk to support melanoma research - melanoma 5k walk ! Slip! Slop! Slap! and Wrap! h/t American Cancer Society If you are going to be in the sun, this catchphrase can help you remember some of the key steps you can take to protect yourself from UV rays:

🚨Hot of the press - Pleased to share our paper 👉🏼just before @esmo #ESMO24 👉🏼⭐️Huge congratulations to our early phase 1 clinical trials team Sarah Cannon Docs for the publication Journal of Clinical Oncology ASCO 👉🏼 First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate

Look who all ran into each other in hall 6 by chance this morning? Sarah Cannon Docs SCRI Oncology Partners strong 💪🏼! At a meeting as big as #ESMO24, you are happy 🥰 when you see your partners! David R. Spigel, MD, FASCO 🫁 Meredith McKean MD, MPH 🌞 ⚠️ #ESMO24 #ESMOAmbassadors

Presented at #ESMO24: Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone. Full CheckMate 067 trial results: nej.md/4dUqm0g